Anuncio
relacionado con: kinnate biopharma south san franciscoClinical stage biotech company revolutionizing the treatment of nerve damage. Restoring life's potential by creating innovative solutions for nerve damage treatment.
Search results
13 de may. de 2024 · Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018.
30 de abr. de 2024 · AbstractPurpose:. Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations.Experimental Design:. A first-in-human, phase ...
14 de may. de 2024 · Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018.
13 de may. de 2024 · Mr. Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018.
Hace 4 días · University of California San Diego Health San Diego, California, United States. Disclosures. Ezra Cohen, MD,FRCPSC, FASCO, has the following relevant financial relationships: ... Stock options from: Kinnate Biopharma; Primmune Therapeutics Owns stock (publicly traded) in: Kinnate Biopharma; ...
27 de abr. de 2024 · Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc. Read time: 1 mins. Published: 27th Apr 2024. XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health...
Hace 6 días · Active Indication - Inactive Indication. Non-Small Cell Lung Cancer. Originator Organization. Kinnate Biopharma, Inc. Active Organization - Inactive Organization. Kinnate Biopharma, Inc. Drug Highest Phase Discontinued Preclinical. First Approval Date - Regulation - Related. 100 Clinical Results associated with KIN-7136. Login to view more data.
Anuncio
relacionado con: kinnate biopharma south san franciscoClinical stage biotech company revolutionizing the treatment of nerve damage. Restoring life's potential by creating innovative solutions for nerve damage treatment.
